Dr. Reddy's Laboratories Ltd Stock 12‑Month Price Target Cut to $13.12, Implies 1% Downside

Analysts' average price target for Dr. Reddy's Laboratories Ltd (RDY) decreased from $13.24 to $13.12, suggesting a 1% downside from the Oct. 23 close. The consensus rating remains 'Hold' among 39 analysts.

Original reporting
Published Oct 24, 2026, 4:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 24, 2026, 4:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Dr. Reddy's Laboratories Ltd Stock 12‑Month Price Target Cut to $13.12, Implies 1% Downside — source image
Decision brief

The 30-second read

$RDYBearishLow
01

Why it matters

A modest downward revision may prompt short‑term selling but is unlikely to cause a large move.

02

Market read

Small‑cap price‑target adjustment with limited trading impact.

03

What to watch

Potential pipeline developments or upcoming regulatory approvals not reflected in the target change.

Relevance 5/10Novelty 5/10Timing: today

Background

The article summarizes a consensus analyst price‑target revision for Dr. Reddy's Laboratories.

Company-level read

Ticker impact

$RDYBearishMedium confidence
Context

Analyst consensus price target for Dr. Reddy's Laboratories was cut from $13.24 to $13.12, implying about 1% downside.

Expected impact

likely modest pressure as the market prices in the lower target

Evidence & confidence

A 1% implied downside is small but may trigger short‑term selling by target‑focused traders.

Market effects

Minor impact on Indian pharma sector as analysts adjust expectations.

Slight bearish bias for Indian equities with similar valuation profiles.

Limited; only affects investors tracking Dr. Reddy's.

Counterpoint

The target cut may be overly cautious; the stock could hold steady if earnings remain strong.

Key entities

  • Dr. Reddy's Laboratories Ltd

    Indian pharmaceutical company listed in the US as RDY.

Related articles

$RDYHigh

Dr.Reddy's Wins Brazil Approval For Generic Ozempic Alternative

Dr. Reddy's Laboratories (RDY) received approval from Brazil's ANVISA for its generic semaglutide injection, a diabetes treatment similar to Novo Nordisk's Ozempic. The product will be marketed in Brazil, a key market with 16.6 million diabetes patients and a $244.6 million semaglutide market. RDY plans to launch the product via a partnership with Ache. RDY stock closed at $14.77, up 3.29%, and is down 0.10% in pre-market trading.

$RDYMed

Dr Reddy's Laboratories Ltd (RDY) (Q2 2027) Earnings Call Highlights: Margin Recovery

Dr. Reddy's Laboratories reported a 1.5% year-over-year revenue decline, driven by lower lenalidomide sales and declines in North America, Europe, and PSAI businesses. The company expects margins to improve with new products and business mix, targeting a 55% gross margin. Semaglutide relaunch is planned for November 2026, and abatacept biosimilar approval is expected by December 2026.

$RDYHigh

DR REDDYS LABORATORIES LTD (RDY): Financial results for H1 2027

DR REDDYS LABORATORIES LTD (RDY) furnished an SEC Form 6-K — earnings release. Exhibit 99.2 CONTACT DR. REDDY’S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. Investor relationS Media relationS AISHWARYA SITHARAM SANTOSH VYAS aishwaryasitharam@drreddys.com santoshvyas@drreddys.com Dr. Reddy’s Q2 & H1FY27 Financia